BRIEF—Zydus Cadila wins tentative approval for Myrbetriq

Zydus Cadila has received tentative approval from the US regulator to market Myrbetriq (mirabegron), an extended-release formulation selective beta 3-adrenoceptor agonist.

The therapy is approved for the treatment of overactive bladder (OAB), a chronic condition of the lower urinary tract characterised by symptoms of urinary urgency, with or without urge incontinence.

The product will be manufactured at the group’s manufacturing facility at SEZ, Ahmedabad.